Profile data is unavailable for this security.
About the company
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
- Revenue in USD (TTM)0.00
- Net income in USD-9.40m
- Incorporated2015
- Employees10.00
- LocationBluejay Diagnostics Inc360 Massachusetts Avenue, Suite 203ACTON 01720United StatesUSA
- Phone+1 (978) 631-0152
- Fax+1 (302) 636-5454
- Websitehttps://bluejaydx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmagreen Biotech Inc | 1.56k | -500.66k | 1.92m | 0.00 | -- | -- | -- | 1,233.70 | -0.0011 | -0.0011 | 0.00 | -0.0045 | 0.0094 | -- | 3.35 | -- | -302.10 | -472.20 | -- | -- | 11.54 | -- | -32,096.15 | -- | 0.0194 | -71.71 | -- | -- | -- | -- | 80.68 | -- | -- | -- |
| Cyclacel Pharmaceuticals Inc | 80.00k | -17.61m | 1.93m | 12.00 | -- | 1.77 | -- | 24.18 | -16.14 | -16.14 | 0.0423 | 0.5534 | 0.0065 | -- | 0.0547 | -- | -142.14 | -57.58 | -327.21 | -69.81 | -- | -- | -21,882.50 | -18,789.29 | -- | -100.52 | 0.00 | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
| Novelstem International Corp | 18.00k | -1.65m | 1.97m | 15.00 | -- | -- | -- | 109.39 | -0.0352 | -0.0352 | 0.0004 | -0.0541 | 0.0081 | -- | 8.00 | -- | -63.77 | -- | -- | -- | -- | -- | -7,867.33 | -- | -- | -2.13 | 2.61 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -12.55m | 2.02m | 4.00 | -- | -- | -- | -- | -28.16 | -28.16 | 0.00 | -0.4439 | 0.00 | -- | -- | 0.00 | -142.80 | -42.39 | -270.23 | -56.41 | -- | -- | -- | -- | -- | -- | 18.20 | -- | -- | -- | 48.52 | -- | -- | -- |
| VG Life Sciences Inc | 0.00 | -4.30m | 2.11m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
| Kiromic Biopharma Inc | 0.00 | -26.21m | 2.20m | 35.00 | -- | -- | -- | -- | -19.73 | -19.73 | 0.00 | -3.35 | 0.00 | -- | -- | 0.00 | -167.49 | -161.04 | -- | -294.57 | -- | -- | -- | -- | -- | -7.22 | 1.74 | -- | -- | -- | 33.00 | -- | 8.52 | -- |
| Zyversa Therapeutics Inc | 0.00 | -21.86m | 2.26m | 7.00 | -- | 0.2131 | -- | -- | -100.63 | -100.63 | 0.00 | 10.32 | 0.00 | -- | -- | 0.00 | -84.85 | -- | -140.95 | -- | -- | -- | -- | -- | -- | -21,828.74 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| Bio Path Holdings Inc | 0.00 | -11.60m | 2.27m | 10.00 | -- | 1.58 | -- | -- | -17.91 | -17.91 | 0.00 | 0.5655 | 0.00 | -- | -- | 0.00 | -199.23 | -70.80 | -321.87 | -76.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.94 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -25.25m | 2.29m | 40.00 | -- | 0.1555 | -- | -- | -46.21 | -45.63 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -115.20 | -47.16 | -160.28 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -9.82m | 2.34m | 8.00 | -- | 0.3719 | -- | -- | -19.42 | -19.42 | 0.00 | 4.79 | 0.00 | -- | -- | 0.00 | -140.74 | -- | -173.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
| Bluejay Diagnostics Inc | 0.00 | -9.40m | 2.35m | 10.00 | -- | 0.0425 | -- | -- | -44.53 | -44.53 | 0.00 | 3.34 | 0.00 | -- | -- | 0.00 | -97.27 | -- | -121.76 | -- | -- | -- | -- | -- | -- | -19.61 | 0.0185 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
| Salarius Pharmaceuticals Inc | 0.00 | -6.46m | 2.46m | 2.00 | -- | 0.4616 | -- | -- | -12.64 | -12.64 | 0.00 | 3.70 | 0.00 | -- | -- | 0.00 | -82.83 | -69.27 | -119.83 | -79.89 | -- | -- | -- | -675.70 | -- | -- | 0.00 | -- | -- | -- | 60.32 | -- | -- | -- |
| Protagenic Therapeutics Inc | 0.00 | -6.40m | 2.50m | 1.00 | -- | 3.16 | -- | -- | -1.45 | -1.45 | 0.00 | 0.1774 | 0.00 | -- | -- | 0.00 | -152.72 | -74.49 | -206.36 | -92.56 | -- | -- | -- | -- | -- | -17.09 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| Qrons Inc | 0.00 | -860.04k | 2.59m | 2.00 | -- | -- | -- | -- | -0.0632 | -0.0632 | 0.00 | -0.088 | 0.00 | -- | -- | 0.00 | -9,368.63 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -9.21 | -- | -- | -- | -- | -7.61 | -- | -- | -- |
| GB Sciences Inc | 0.00 | -1.64m | 2.65m | 2.00 | -- | -- | -- | -- | -0.0041 | -0.0041 | 0.00 | -0.0131 | 0.00 | -- | -- | 0.00 | -597.54 | -31.80 | -- | -297.29 | -- | -- | -- | -- | -- | -6.49 | -- | -- | -- | -- | 60.24 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Bluejay Diagnostics Inc's reporting currency: US Dollar USD
2.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Anson Funds Management LPas of 30 Jun 2024 | 69.51k | 1.11% |
| Heights Capital Management, Inc.as of 30 Jun 2024 | 66.17k | 1.06% |
| Virtu Americas LLCas of 30 Jun 2024 | 17.05k | 0.27% |
| L1 Capital Global, Inc.as of 27 Jun 2024 | 16.77k | 0.27% |
| Warberg Asset Management LLCas of 30 Jun 2024 | 12.50k | 0.20% |
| Tower Research Capital LLCas of 30 Jun 2024 | 4.30k | 0.07% |
| Citadel Securities LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Jun 2024 | 0.00 | 0.00% |
| XTX Markets LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 29 Aug 2024Source: FactSet Research Systems Inc.
